NCT07753200RecruitingPhase 4
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
Non-vitamin K antagonist oral anticoagulants(NOACs) are standard care for thromboembolism prevention in patients with Aterial Fibrillation(AF). However, evidence comparing edoxaban and apixaban remains limited in AF patients with coexisting coronary artery disease(CAD). This study aims to evaluate whether edoxaban-based therapy is non-interior to apixaban-based therapy with respect to Net Adverse Clinical Events(NACE) in AF patients with concomitant CAD.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 3000 (estimated)
- First submitted
- 31 Jul 2026
- Start date
- 20 Jul 2026
- Primary completion date
- 1 Jun 2031
- Lead sponsor
- Samsung Medical Center
- NCT number
- NCT07753200
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 3000
- From 20 Jul 2026 to the primary completion date, 1 Jun 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Indication requiring alternative anticoagulation (e.g., mechanical valve surgery or moderate / severe mitral stenosis)
Other illness
- Known hypersensitivity or contraindications to study medications (apixaban or edoxaban)
- Active major bleeding
- Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
Lab values
- Severe renal impairment (creatinine clearance \<15 mL/min) or dialysis
Other
- Pregnant or lactating women
Who the study is looking for
- Patients must be at least 19 years of age
- Patients with AF requiring oral anticoagulation therapy (CHA2DS2-VaSc 2 or more)
- Documented coronary artery disease, defined as at least one of the following: history of percutaneous coronary intervention (PCI), history of coronary artery bypass grafting (CABG), major epicardial coronary artery stenosis ≥50% on coronary computed tomography angiography (CCTA) or invasive coronary angiography
- Patients who can understand risks, benefits and treatment alternatives and sign informed consent voluntarily.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.